Thryv Therapeutics

Publications and Presentations

Our clinical and preclinical data sets presented at leading medical and scientific forums, alongside select reference publications from the broader scientific community, spanning Long QT Syndrome, heart failure, cardiometabolic disease and atrial fibrillation.

New in JACC: Heart Failure

Genetic, Preclinical, and Clinical Evidence Supports SGK1 Inhibition in Heart Failure

Open access · September 2026

Read publication↗

LATEST · AHA Scientific Sessions 2026

SGK1 Inhibition, Monotherapy Or In Combination With Incretin Agonism, Targets Residual Risk In Cardiometabolic Heart Failure
Late-breaking · November 7, 2026 · 2:30 PM to 3:30 PM

What is the Lived Experience and Symptom Burden of Patients with Long QT Syndrome Type 2 & Type 3? Initial Findings from the myQTwave National Survey
Poster · November 8, 2026 · 11:30 AM to 12:30 PM

Long QT Syndrome

PUBLICATIONS


May 2026

SGK1-inhibition restores cardiac repolarization in LQT2 rabbits and LQT3 mice by reducing late sodium current

Pharmacological Research

View publication ↗


November 2025

SGK1 inhibition shortens action potential duration and exerts anti-arrhythmic effects in LQT3 mice and LQT2 rabbits by reducing enhanced late sodium current

European Heart Journal

View publication ↗


May 2023

Gene and variant-specific efficacy of serum/glucocorticoid-regulated kinase 1 inhibition in long QT syndrome types 1 and 2

EP Europace

View publication ↗


April 2023

SGK1 inhibition attenuates the action potential duration in reengineered heart cell models of drug-induced QT prolongation

Heart Rhythm

View publication ↗


February 2023

SGK1 inhibition attenuated the action potential duration in patient- and genotype-specific re-engineered heart cells with congenital long QT syndrome

Heart Rhythm O2

View publication ↗


PRESENTATIONS


November 2026

What is the Lived Experience and Symptom Burden of Patients with Long QT Syndrome Type 2 & Type 3? Initial Findings from the myQTwave National Survey

American Heart Association Scientific Sessions


April 2025

SGK-1 inhibition with LQT-1213 significantly reduces the QTcF in patients with congenital Long QT Syndrome in the Wave I, Part 2 study

Heart Rhythm Society Annual Meeting · San Diego, CA

View abstract ↗


November 2024

SGK1 inhibition shortens action potential duration in LQT3 mice and LQT2 rabbits via inhibition of late sodium current

American Heart Association Scientific Sessions · Chicago, IL

View abstract ↗


May 2024

Attenuation of drug-induced QT prolongation in guinea pig isolated heart and anesthetized dog models of drug-induced QT prolongation by serum/glucocorticoid regulated kinase 1 (SGK-1) inhibitors

Heart Rhythm Society Conference · Boston, MA

View abstract ↗


March 2024

SGK-1 inhibitor attenuates QTcF prolongation in a dofetilide-induced human model (Wave I clinical study)

American College of Cardiology Conference · Atlanta, GA

View abstract ↗


November 2022

SGK1 inhibition attenuated the action potential duration in patient- and genotype-specific re-engineered heart cells with congenital Long QT Syndrome

AHA Scientific Sessions · Chicago, IL

View poster ↗


November 2022

SGK1 inhibition and attenuation of action potential duration in re-engineered heart cell models of drug-induced QT prolongation

AHA Scientific Sessions · Chicago, IL

View poster ↗


REFERENCE PUBLICATIONS


November 2025

Long QT Syndrome (review)

New England Journal of Medicine

View publication ↗


March 2017

Inhibition of serum and glucocorticoid regulated kinase-1 as novel therapy for cardiac arrhythmia disorders

Scientific Reports

View publication ↗


June 2003

Modulating effects of age and gender on the clinical course of Long QT Syndrome by genotype

JACC Journals

View publication ↗


May 2003

Risk stratification in the Long-QT Syndrome

New England Journal of Medicine

View publication ↗


February 2000

Effectiveness and limitations of β-blocker therapy in congenital Long-QT Syndrome

Circulation

View publication ↗


Heart Failure and Cardiomyopathies

PUBLICATIONS


September 2026

Genetic, preclinical, and clinical evidence supports SGK1 inhibition in heart failure

JACC: Heart Failure

View publication ↗


November 2025

A novel serum glucocorticoid regulated kinase 1 inhibitor improves cardiac structure and function in heart failure (pre-print)

Sciety

View publication ↗


PRESENTATIONS


November 2025

Small molecule inhibitors of serum glucocorticoid kinase 1 (SGK1) prevent cardiac structural and functional decline in a transverse aortic constriction (TAC) model

AHA Scientific Sessions · New Orleans, LA

View abstract ↗


November 2025

THRV-1268, a potent and selective serum and glucocorticoid regulated kinase (SGK1) inhibitor, improves adverse cardiac remodeling better than Jardiance® (empagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor in heart failure

AHA Scientific Sessions · New Orleans, LA

View abstract ↗


November 2025

The serum and glucocorticoid regulated kinase 1 (SGK1) inhibitor THRV-1268 attenuates hallmarks of heart failure by reducing inflammation and fibrosis beyond sodium/glucose cotransporter 2 inhibition

AHA Scientific Sessions · New Orleans, LA

View abstract ↗


August 2025

THRV-1268, a novel and potent SGK1 inhibitor, improved adverse cardiac remodeling beyond empagliflozin, an SGLT2 inhibitor, by reducing inflammation and fibrosis mechanisms in heart failure

European Society of Cardiology (ESC) Congress · Madrid, Spain

Watch ESC presentation ↗‍ ‍ ‍ ‍View presentation ↗


November 2024

Serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor reduced hypertension in a salt-sensitive hypertension model of heart failure with preserved ejection fraction

AHA Scientific Sessions · Chicago, IL

View abstract ↗


November 2024

SGK1 inhibition attenuated left ventricular thickening and diastolic dysfunction in a mouse model of HFpEF

AHA Scientific Sessions · Chicago, IL

View abstract ↗


November 2024

Serum and glucocorticoid regulated kinase 1 (SGK1) inhibition induces anti-fibrotic and anti-inflammatory responses: relevance to cardiac fibrosis

AHA Scientific Sessions · Chicago, IL

View abstract ↗


REFERENCE PUBLICATIONS


January 2026

Cardiovascular statistics in the United States

JACC Journals

View publication ↗


January 2026

One-Year Outcomes in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction Prescribed Quadruple Medical Therapy at Discharge

JAMA Cardiology

View publication ↗


October 2024

Serum and glucocorticoid-regulated kinase 1 (SGK1) as an emerging therapeutic target for cardiac diseases

Pharmacological Research

View publication ↗


September 2023

New challenges in heart failure with reduced ejection fraction: managing worsening events

Journal of Clinical Medicine

View publication ↗


October 2012

Pathological Role of Serum- and Glucocorticoid-Regulated Kinase 1 in Adverse Ventricular Remodeling

Circulation

View publication ↗


April 2003

QTc interval and B-type natriuretic peptide levels predict death in patients with advanced heart failure

Circulation

View publication ↗


Cardiometabolic disease

Presentations


November 2026

SGK1 Inhibition, Monotherapy Or In Combination With Incretin Agonism, Targets Residual Risk In Cardiometabolic Heart Failure

American Heart Association Scientific Sessions


July 2026

A Potent Serum and Glucocorticoid-Regulated Kinase 1 (SGK1) Inhibitor is Protective in a Model of CKMD

Basic Cardiovascular Sciences (BCVS) Scientific Sessions


Atrial Fibrillation


PRESENTATIONS


November 2023

A novel SGK1 inhibitor (SGK1-I) prevents obesity-related atrial fibrillation

American Heart Association Scientific Sessions · Philadelphia, PA

View abstract ↗


Reference publications


August 2022

Genetic inhibition of serum glucocorticoid kinase 1 prevents obesity-related atrial fibrillation

JCI Insight

View publication ↗